Gopan Gayathri, Anoop T M, Prakash N P, Nambiar Rakul, Krishnachandran R
Department of Medical Oncology, Regional Cancer Centre, Thiruvananthapuram, Kerala, India.
Department of Cancer Research, Regional Cancer Centre, Thiruvananthapuram, Kerala, India.
Indian J Pathol Microbiol. 2017 Oct-Dec;60(4):593-595. doi: 10.4103/IJPM.IJPM_357_17.
Myeloid and lymphoid hematological malignancies with eosinophilia and abnormalities of fibroblast growth factor receptor-1 (FGFR1) result from the formation of abnormal fusion genes that encode constitutively activated tyrosine kinases. The WHO classification (2008) of hematolymphoid neoplasms recognizes a category of myeloid and lymphoid neoplasms with eosinophilia and abnormalities of FGFR1. Here, we present the case of a 30-year-old-woman who was diagnosed with T-lymphoblastic lymphoma from lymph node biopsy and myeloproliferative neoplasm with eosinophilia from bone marrow studies. She was treated with combination chemotherapy with cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD regimen) and is on maintenance chemotherapy for the past 2 months. We present this case to create awareness among physicians about this rare condition associated with dual malignancies.
伴有嗜酸性粒细胞增多和成纤维细胞生长因子受体1（FGFR1）异常的髓系和淋巴系血液系统恶性肿瘤是由编码组成型激活酪氨酸激酶的异常融合基因形成所致。世界卫生组织（2008年）血液淋巴系统肿瘤分类认可了一类伴有嗜酸性粒细胞增多和FGFR1异常的髓系和淋巴系肿瘤。在此，我们报告一例30岁女性病例，该患者经淋巴结活检诊断为T淋巴母细胞淋巴瘤，经骨髓检查诊断为伴有嗜酸性粒细胞增多的骨髓增殖性肿瘤。她接受了环磷酰胺、长春新碱、阿霉素和地塞米松联合化疗（Hyper-CVAD方案），并在过去2个月接受维持化疗。我们报告此病例是为了提高医生对这种与双重恶性肿瘤相关的罕见疾病的认识。
